Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations and Comprehensive Loss

v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Research and development $ 9,904,225 $ 13,005,986
General and administrative 6,800,190 3,155,735
Total operating expenses 16,704,415 16,161,721
Loss from operations (16,704,415) (16,161,721)
Other income 0 171,282
Interest income 2,987,521 404,020
Net loss (13,716,894) (15,586,419) [1]
Other comprehensive income (loss):    
Foreign currency translation (loss) gain, net (4,189) 1,630
Unrealized gain on investments, net 99,586 48,494
Comprehensive loss $ (13,621,497) $ (15,536,295)
Net loss per share:    
Basic and diluted (in dollars per share) $ (1.85) $ (4.11) [1]
Weighted average shares outstanding:    
Basic and diluted** (in shares) [2] 7,411,121 3,790,202 [1]
[1] Information pertaining to the number of shares outstanding gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024.
[2] Information pertaining to number of shares outstanding and per share data gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024.